Lymphoma

There are limits and adaptations that are needed during childhood, adulthood and retirement, and I can say the same for every step of my cancer experience.

Two decades ago, I received a stage 4 lymphoma diagnosis, and since then, I’ve learned that life goes on — even with cancer.

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.

We’ve all heard the jokes about hospital food.

A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.

While much progress has been made in treating blood cancers like lymphoma, I know that there is still far more work to be done.

The very first blog I ever wrote for CURE asked the question, “Why me?”

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

I don’t know about you, but music moves me. Literally. It makes me move.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.

Here’s a look back at blood cancer approvals from the summer of 2023.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, about the current research in treatments.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, who discussed recent treatment advancements and FDA approvals.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

A phase 1 clinical trial just launched and will test the novel agent, CLN-978, for relapsed/refractory B-cell non-Hodgkin lymphoma.

Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”

One of the most common side effects of cancer treatment must be the chills, feeling cold all the time.

When paired with the chemotherapy combination doxorubicin, vinblastine and dacarbazine, Keytruda resulted in 100% overall survival in the findings from a new study of adult patients with classic Hodgkin lymphoma.

Being treated for Hodgkin lymphoma during childhood can result in fertility declines, a recent study shows.

Patients with advanced cancers who live in states that expanded Medicaid were more likely to receive early palliative care, although utilization remains low in the U.S.

Patients with depression or anxiety at the time of a diffuse large B-cell lymphoma diagnosis tended to have worse survival, recent research showed.

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.